All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the GvHD Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss infection prophylaxis for patients with graft-versus-host disease (GvHD). The discussion was chaired by Professor Mohamad Mohty and featured Frederic Baron, Yi-Bin Chen, Amin Alousi, Florent Malard, Arnon Nagler, Zinaida Peric, and Robert Zeiser.
Infection prophylaxis for patients with GvHD
The steering committee discussed the strategies to manage infections and choices of antibiotics to reduce GvHD-related mortality, the effect of diet on the gut microbiome and GvHD severity, and how to personalize prophylaxis. They also spoke about integration of microbiota therapy into GvHD prophylaxis.
Subscribe to get the best content related to GvHD delivered to your inbox